# Quest Diagnostics account plan

> Quest Diagnostics is a US clinical laboratory company with 2025 net revenues of $11,035 million and nearly 57,000 employees.

## At a glance

Quest Diagnostics provides diagnostic testing in the United States, serving about one-third of US adults and about half of US physicians and hospitals each year through ~2,400 patient service centers; it also operates LifeLabs in Canada. 2025 net revenues were $11,035 million (+11.8%; organic growth 5.3%), with operating income of $1,556 million and net income attributable to Quest of $992 million. It processed ~244 million test requisitions in 2025 and has nearly 57,000 employees. Its customers are physicians, hospitals, payers, life insurers and consumers.

## Business units

- **Diagnostic Information Services (DIS)** (97.7% of 2025 revenue ($10,785 million)): Clinical lab testing for physicians, hospitals and consumers, including Advanced Diagnostics (over $1 billion on double-digit growth), hospital reference testing and Collaborative Lab Solutions. Q3 2026 DIS revenues were $3,035 million (+10.2%).
- **Diagnostic Solutions (DS)** (2.3% of 2025 revenue ($250 million)): ExamOne risk assessment for life insurers and healthcare IT such as Quanum. Q3 2026 revenues were $62 million.

## Strategic priorities

- **Growth across physician, hospital and consumer channels**: High single-digit growth in physicians, double-digit growth in hospitals in Q3 2026, and consumer health growth expected to exceed 30% for the year.
- **Collaborative Lab Solutions with health systems**: Co-Lab Solutions across all 21 Corewell Health hospitals; Co-Lab Solutions is expected to generate about $1 billion of revenue in 2026.
- **Outreach and lab acquisitions**: M&A targets 1-2% revenue growth a year, including an agreement to acquire outreach lab assets from a Northeastern US health system.
- **Consumer channel**: QuestHealth.com is a $100 million run-rate business; an Apple Health app panel of over 50 biomarkers launches around year-end, with partners including WHOOP, Oura and Function Health.
- **Cost savings through Invigorate, automation and AI**: Invigorate targets 3% annual cost savings; automated aliquoting runs in 10 labs and AI collaboration is under way with Google Cloud.

## Latest results

In Q3 2026 net revenues were $3,097 million (+10.0%), with DIS organic growth of 10.1% and volume up 14.5%, of which 9.5% came from the Corewell Health relationship and Fresenius dialysis testing. Revenue per requisition fell 4.2% because of that routine-testing mix. Reported diluted EPS was $2.78 and adjusted diluted EPS $3.00 (+15.4%). Full-year 2026 guidance was raised to revenues of $12.065-12.105 billion and adjusted EPS of $11.25-11.35, with capex of about $550 million.

## Investments and deals

- **Corewell Health joint venture**: 51/49 lab JV in Michigan closed in January 2026; a new Michigan lab is due to be operational during 2027.
- **Project Nova**: Epic-based modernization of Order to Cash running to 2031-2032; it moved to build phase with the first Epic lab deployment in fall 2027.
- **Lab asset acquisitions**: Spectra Laboratories assets bought from Fresenius for $84 million; LifeLabs acquired in 2024.
- **Capex and shareholder returns**: Capex was $527 million in 2025 and is guided at about $550 million for 2026; an additional $1 billion buyback was authorized and the dividend raised 7.5% to $0.86 per quarter.

## Challenges and risks

- **PAMA Medicare fee cuts**: The 2027 impact is estimated at about 1% of total revenues; Quest lobbies for the RESULTS Act.
- **Payer and policy pressure**: Payer utilization controls, OBBBA and expiry of ACA tax credits could cost up to 50-60 bp of revenue by 2028.
- **Cybersecurity**: A cybersecurity incident on a test-ordering system was disclosed on October 22, 2026.
- **Pricing mix and competition**: Unit price is generally flat, and Quest competes with hospital labs and Laboratory Corporation of America; labor supply is a stated risk.

## What leadership says

> "We delivered revenue growth of 10% and adjusted EPS growth of over 15% on continued strength across our physician, hospital and consumer channels, complemented by productivity gains from automation and AI." — Jim Davis, Chairman, CEO and President, Q3 2026 results press release, 2026-10-22

> "We expect co-lab solutions to generate approximately $1 billion in annual revenues in 2026." — Jim Davis, Chairman, CEO and President, Q4 2025 earnings call, 2026-02-10

> "further advanced our position as the premier lab engine powering the wellness industry" — Jim Davis, Chairman, CEO and President, Q4 2025 earnings call, 2026-02-10


## Where a supplier can help

- **Lab automation and AI**: The Invigorate 3% savings target and automation and AI in labs open doors for lab robotics, AI imaging and workflow vendors.
- **Epic migration support**: Project Nova's Epic-based Order to Cash modernization needs implementation, data migration and testing partners through 2031-2032.
- **Security of ordering systems**: The cybersecurity incident on a test-ordering system makes security assessment and monitoring services relevant.
- **Consumer and digital health partnerships**: The consumer channel and the Apple Health app panel call for digital marketing, ecommerce and wearables integration partners.
- **Health system lab outsourcing**: Co-Lab Solutions and the new Michigan lab create needs for lab construction, equipment and logistics suppliers.

_Tamtam's reading of the priorities and challenges above, not the company's own words._

## Key documents

### [Annual Report on Form 10-K for fiscal year 2025](https://www.sec.gov/Archives/edgar/data/1022079/000102207926000015/dgx-20251231.htm)

Annual report · 2026-02-26

- Quest Diagnostics is the US clinical lab leader: 2025 net revenues of $11,035 million (+11.8%; organic growth 5.3%), operating income $1,556 million, net income attributable to Quest $992 million, diluted EPS $8.75, operating cash flow $1,886 million, capex $527 million.
- Two businesses: Diagnostic Information Services (DIS, $10,785 million, 97.7% of revenue, the only reportable segment) and Diagnostic Solutions (DS, $250 million, 2.3%: ExamOne risk assessment for life insurers and healthcare IT such as Quanum).
- Scale: serves about one-third of US adults annually and about half of US physicians and hospitals; ~244 million test requisitions in 2025; ~2,400 patient service centers; >80 billion patient data points; nearly 57,000 employees (incl. ~6,800 at LifeLabs in Canada).
- Customer channels are physicians, hospitals (reference testing ~$1.2 billion; Collaborative Lab Solutions ~$800 million) and patients/consumers (QuestHealth.com, 150+ tests); Advanced Diagnostics generated over $1 billion on double-digit growth.
- Growth via outreach and lab acquisitions (target 1-2% revenue growth a year from M&A): Spectra Laboratories assets from Fresenius ($84 million), 51/49 lab JV with Corewell Health in Michigan; LifeLabs acquired in 2024.
- Efficiency: Invigorate targets 3% annual cost savings; Project Nova, an Epic-based modernization of "Order to Cash", runs to 2031-2032; AI collaboration with Google Cloud.
- Payer mix of DIS revenue: healthcare insurers 39%, client payers 31%, government 16%, patients 12%; capitated arrangements ~8% of revenue.
- Main risks: PAMA Medicare fee cuts (delayed repeatedly), payer utilization controls, OBBBA and expiry of ACA tax credits (up to 50-60 bp of revenue by 2028), competition from hospital labs and Laboratory Corporation of America, cybersecurity, labor supply.
- Capital return: dividend raised 7.5% to $0.86 per quarter in February 2026; additional $1 billion buyback authorized; ~$8.1 billion returned through buybacks since 2012.

### [Quarterly Report on Form 10-Q for Q3 2026 (quarter ended September 30, 2026)](https://www.sec.gov/Archives/edgar/data/1022079/000102207926000108/dgx-20260930.htm)

Interim report · 2026-10-23

- Q3 2026 net revenues $3,097 million (+10.0%), DIS revenues $3,035 million (+10.2%, organic growth 10.1%), DS revenues $62 million.
- Nine months: net revenues $9,035 million (+9.8%, organic revenue growth 9.6%); operating income $1,337 million (+14.3%); net income attributable to Quest $884 million; diluted EPS $7.86 (+19.6%).
- Q3 DIS volume +14.5% (organic +14.4%), of which 9.5% came from the new Corewell Health Collaborative Lab Solutions relationship and higher testing at Fresenius Medical Care dialysis clinics; excluding them volume grew 5%.
- Revenue per requisition fell 4.2% because the Corewell/Fresenius work is mostly routine testing; excluding that mix it rose 1.7%, on more tests per requisition.
- Q3 operating income $479 million (15.5% margin vs 13.7%); diluted EPS $2.78 vs $2.16.
- The Corewell Health JV (51% Quest / 49% Corewell) closed in January 2026 and is consolidated; a new Michigan lab is due to be operational during 2027.
- Invigorate still targets 3% annual cost savings; Project Nova spend is adding to SG&A.
- Balance sheet: $500 million of 5.00% notes due 2036 issued in May 2026 to repay 3.45% notes; $250 million of buybacks in nine months; quarterly dividend $0.86; $1.2 billion of buyback authorisation left.

### [Q3 2026 financial results press release (8-K Exhibit 99.1): raises 2026 guidance](https://www.sec.gov/Archives/edgar/data/1022079/000102207926000097/dgx093020268-kex991.htm)

Interim report · 2026-10-22

- Q3 2026 revenues $3.10 billion, up 10.0%; reported diluted EPS $2.78 (+28.7%); adjusted diluted EPS $3.00 (+15.4%).
- Adjusted operating income $517 million, 16.7% of revenues (16.3% a year earlier).
- Full-year 2026 guidance raised: revenues $12.065-12.105 billion (+9.3% to 9.7%; prior $11.95-12.05 billion), reported EPS $10.21-10.31, adjusted EPS $11.25-11.35, operating cash flow about $1.90 billion, capex about $550 million.
- Jim Davis credits strength "across our physician, hospital and consumer channels, complemented by productivity gains from automation and AI".
- Highlights: Apple Health app users will be able to buy a Quest panel of over 50 biomarkers; agreement to acquire outreach lab assets from a Northeastern US health system; AD-Detect panel with Roche pTau217; Project Nova moved to build phase with the first Epic lab deployment in fall 2027.
- Investor Day on March 25, 2027 at the NYSE; the release flags the cybersecurity incident disclosed in an 8-K the same day.

### [Quest Diagnostics Q3 2026 earnings call transcript](https://fortune.com/company/quest-diagnostics/earnings/q3-2026/)

Executive talk · Jim Davis, Chairman, CEO and President (with Sam Samad, CFO) · 2026-10-22

- Q3 2026 revenues grew 10% and adjusted EPS over 15%; guidance raised to revenues of $12.065-12.105 billion and adjusted EPS of $11.25-11.35.
- Growth was broad: high single-digit revenue growth in physicians, double-digit growth in hospitals (driven by Co-Lab Solutions with Corewell Health), and consumer health growth expected to exceed 30% for the year.
- Volume excluding Corewell and Fresenius grew 5%; unit price "generally flat"; consumer margins are accretive (no denials, no patient concessions, dense requisitions).
- New consumer channel: an Apple Health app panel of over 50 biomarkers at "$119 rack", launching around year-end.
- Kidney care: Quest fielded a specialized sales force for nephrologists after taking on Fresenius dialysis testing.
- PAMA: 2027 impact estimated at about 1% of total revenues (under 1.3% cumulative for 2027-2029); Quest will offset part of it and lobbies for the RESULTS Act; Davis calls the CMS data collection "flawed".
- Automation and AI: automated aliquoting in 10 labs; AI scanning dialysis water samples at Clifton, NJ; Invigorate delivering 3% savings.
- A cybersecurity incident on a test-ordering system was disclosed the same day; management gave no further detail.

### [Quest Diagnostics Q4 and full-year 2025 earnings call transcript](https://fortune.com/company/quest-diagnostics/earnings/q4-2025/)

Executive talk · James E. Davis, Chairman, CEO and President (with Sam Samad, CFO) · 2026-02-10

- 2025 delivered double-digit growth in revenues and EPS; Q4 revenues $2.81 billion (+7.1%, organic 6.4%), adjusted EPS $2.42.
- Initial 2026 guidance: revenues $11.7-11.82 billion (+6% to 7.1%), adjusted EPS $10.50-10.70, operating cash flow about $1.75 billion, capex about $550 million; no PAMA impact in 2026 after a one-year delay.
- Corewell Health: Co-Lab Solutions across all 21 Corewell hospitals, the largest to date, adding about $250 million of organic revenue at low single-digit margins in 2026; Co-Lab Solutions expected to generate about $1 billion of revenue in 2026.
- Fresenius Medical Care: Quest scaled testing to more than 200,000 patients at its US dialysis centers.
- Consumer channel: nearly $250 million of revenue in 2025; QuestHealth.com a $100 million run-rate business that grew about 35%; partners include WHOOP, Oura and Function Health; long-term target above 20% growth.
- Davis sees share gains against hospital outreach and physician office labs, helped by re-entering Elevance networks in several states and Sentara; Quest has over 1,200 sales reps.
- Innovation: AD-Detect Alzheimer's tests, ANAlyzer autoimmune, Haystack MRD and a new Flow MRD myeloma test; data business growing double digits.
- Project Nova costs about $0.25 of EPS in 2026; Davis pushes the RESULTS Act to fix PAMA.

## Questions about Quest Diagnostics

### What does Quest Diagnostics do?

Quest Diagnostics runs clinical laboratory testing for physicians, hospitals, payers and consumers in the United States, plus risk assessment for life insurers and healthcare IT.

### What is Quest Diagnostics' revenue?

2025 net revenues were $11,035 million (+11.8%). 2026 guidance is $12.065-12.105 billion.

### How many employees does Quest Diagnostics have?

Nearly 57,000, including ~6,800 at LifeLabs in Canada.

### Who leads Quest Diagnostics?

Jim Davis is Chairman, CEO and President, and Sam Samad is CFO.

_Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)_
